Clinical trial
Treatment of Alzheimer's Disease With CX516 (Ampalex)
NCT00001662 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00001662 |
|---|---|
| Title | Treatment of Alzheimer's Disease With CX516 (Ampalex) |
| Official title | Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Dementia |
| Intervention type | Drug |
| Interventions | CX516 (Ampalex) |
| Enrollment | 40 |
| Start date | Dec 1, 1996 |
| Completion | Nov 1, 2005 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: